Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by
Negative impact of the IRA on patient access to innovative treatments

Negative impact of the IRA on patient access to innovative treatments
angilma1

/by
Novartis statement on Maximum Fair Price for Entresto

Novartis statement on Maximum Fair Price for Entresto
angilma1

/by
Every number has a story – my journey to Novartis as a Refugee

Every number has a story – my journey to Novartis as a Refugee
tavasat1

/by
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Is Diversity, Equity and Inclusion (DEI) really that important?

Is Diversity, Equity and Inclusion (DEI) really that important?
mihai_novartis

/by
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 

Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML 
arcticnovartis

  • Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of care therapies (imatinib and 2G TKIs)1 
  • Treatment options combining high efficacy with safety and tolerability represent a critical gap in care for long-term CML management1
/by
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024

Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
arcticnovartis

Annonce événementielle au sens de l’art. 53 RC

Résultats du deuxième trimestre (T2)

/by